The Makers of TYLENOL® Select Winners of 22nd Annual Future Care Scholarship Fund - The Sacramento Bee
|
McNeil Consumer Healthcare Division of McNEIL-PPC, Inc., the makers of TYLENOL®, announces the 40 recipients of the 22nd annual TYLENOL® Future Care Scholarship. The 2012 program awards a total of $250,000 in scholarship funds to undergraduate and graduate students pursuing careers in healthcare. ... Brook Wilson, a Physician Assistant student at the Texas Tech University Health Sciences Center, said, "I will know I have truly crossed the finish line when I am able to offer my patients the comprehensive, patient-centered, ethical care they deserve." Read the full story >> |
Related Stories
How Does Your Garden Grow?
As spring approaches, some people’s thoughts turn to gardening. Whether it’s a flower garden they desire or a vegetable garden want to have, they begin planning what they’ll plant and what they need to do to ensure a successful garden.
Adopt a Growth Mindset for a Better Life
A “growth mindset” accepts that our intelligence and talents can develop over time, and a person with that mindset understands that intelligence and talents can improve through effort and learning.
Drug Use, Family History Can Lead to Heart Disease in Younger Adults
Abstaining from drug abuse and an early diagnosis of familial hypercholesterolemia (high cholesterol) can help prevent heart disease.
Recent Stories
TTUHSC School of Medicine Faculty Member Elected to the Texas Medical Association Board of Trustees
The Texas Medical Association (TMA) elected Rodney Young, M.D., to the TMA Board of Trustees during TexMed 2024, its annual conference in Dallas.
Texas Tech Physicians Announces Website Redesign
This May, Texas Tech Physicians announced the launch of its newly redesigned website. TTUHSC experts address a few questions about the new user experience.
TTUHSC’s Ahmed Investigating Cardiac Cell Regeneration
Mahmoud Salama Ahmed, Ph.D., and an international team of researchers have completed an investigation to uncover novel therapeutics or existing therapeutic regimens previously approved by the FDA for cardiac regeneration.